By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

Data from a late-stage trial, presented on Sunday, indicate that the treatment, administered six months before and after ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Johnson & Johnson is proposing a solution to a longstanding prostate cancer treatment gap. | In its 2,000-patient Proteus ...

Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after ...

Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

Think surgery automatically means spending days in hospital? Not always. Doctors explain how modern techniques are making day ...

A 77-year-old man suffering from a severely enlarged prostate was treated using an advanced minimally invasive laser ...

Apollo Hospitals Chennai, a leader in robotic-assisted cancer care, has performed the world's first Video Endoscopic Inguinal ...

The study, which followed patients for over five ‌years, found that those ⁠who received ⁠the regimen were nine times more ...